Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.9413
+0.0833 (9.71%)
Oct 9, 2025, 11:25 AM EDT - Market open
Cue Biopharma Employees
Cue Biopharma had 41 employees as of December 31, 2024. The number of employees decreased by 12 or -22.64% compared to the previous year.
Employees
41
Change (1Y)
-12
Growth (1Y)
-22.64%
Revenue / Employee
$202,098
Profits / Employee
-$948,659
Market Cap
72.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41 | -12 | -22.64% |
| Dec 31, 2023 | 53 | 1 | 1.92% |
| Dec 31, 2022 | 52 | -7 | -11.86% |
| Dec 31, 2021 | 59 | 7 | 13.46% |
| Dec 31, 2020 | 52 | 5 | 10.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CUE News
- 10 days ago - Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates - GlobeNewsWire
- 7 weeks ago - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - GlobeNewsWire
- 2 months ago - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - GlobeNewsWire
- 3 months ago - Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire
- 3 months ago - Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease - GlobeNewsWire
- 5 months ago - Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire